Seeks to in-license or acquire therapeutic candidates for development in diseases with significant unmet medical need.
$12.8M
10-K for FY2025, filed Mar 27, 2026
$12.8M ↗No. It lost $71.4M in FY2025.
10-K for FY2025, filed Mar 27, 2026
−$71.4MView ↗
10-Q for Q3 FY2026, filed Nov 16, 2026
−$4.2MView ↗
8-K, filed Apr 3, 2026
On April 1, 2026, the Audit Committee of the Board of Directors of Instil Bio, Inc. (the “Company”) approved the appointment of RSM US LLP…View ↗
Growing. Revenue grew 160.3x in 4 years, from $80K in FY2021 to $12.8M in FY2025, about 256% a year.
From cell therapy to candidate acquisition
The older report describes a pipeline of engineered tumor-infiltrating lymphocyte therapies for cancer. The latest report instead focuses on seeking to in-license or acquire therapeutic candidates for development.
10-K for FY2022, filed Mar 31, 2023
Loading...